AMAG Pharma Reports New Data From Ferumoxytol Pivotal Phase III Broad Iron …

Published December 11, 2012

AMAG Pharma Reports New Data from Ferumoxytol Pivotal Phase III Broad Iron …

Filed under: drug treatment programs in georgia

… Ferumoxytol Pivotal Phase III Broad Iron Deficiency Anemia Program. Paul Quintaro Benzinga. AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that new data from two pivotal phase III clinical trials were presented at the American Society of …
Read more on Equities.com

Pomalidomide: The Next New Drug for Multiple Myeloma

Filed under: drug treatment programs in georgia

ATLANTA, Georgia — Pomalidomide (Celgene) is the next new drug for multiple myeloma, expected to be approved early in 2013. … It offers a treatment for those patients who have stopped responding to thalidomide and lenalidomide, he added.
Read more on Medscape

Aeterna Zentaris: Final Phase 2 Data Demonstrate Perifosine and Sorafenib …

Filed under: drug treatment programs in georgia

Treatment plan included an initial 4 week treatment with perifosine (50 mg BID, per os) to assess tolerability and tumor response. Subsequently, patients achieving less than partial response ("PR") were given perifosine (50 mg BID, per os) combined …
Read more on Sacramento Bee